glp-1 drugs compounding pharmacy Compound versions of for weight loss halted by FDA APC's Scott Brunner on GLP-1

doi:10.1002/bdd.2279 181

[87] found that chronic liraglutide treatment improved nitric oxide (NO)-mediated vasodilation in both the coronary arteries and microcirculation, partially normalizing myocardial remodeling independent of body weight or blood glucose changes

Also, at $500 a month, even the discounted direct-to-consumer price still makes the drugs unaffordable to many

Ther Adv Drug Saf

Weight loss drugs are prescribed to individuals with obesity or individuals who are overweight and managing a weight-related health condition

2 Experts recommend that patient-specific considerations and shared decision-making should be incorporated into treatment decisions